Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Beneish M-Score: -2.26 (As of Jul. 07, 2026)


SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
95 GF Score
Price ¥55.10
GF Value ¥47.90
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co Beneish M-Score?

Chengdu Easton Biopharmaceuticals Co SHSE:688513 -6.15% 95 Beneish M-Score is -2.26 as of Jul. 07, 2026. GuruFocus rates SHSE:688513 with a GF Score™ of 95/100 and a GF Value™ of ¥47.90 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 824 Biotechnology companies, Chengdu Easton Biopharmaceuticals Co ranks worse than 53.64% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.26 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Chengdu Easton Biopharmaceuticals Co's Beneish M-Score or its related term are showing as below:

SHSE:688513' s Beneish M-Score Range Over the Past 10 Years
Min: -2.68   Med: -2.23   Max: 2.4
Current: -2.26

During the past 13 years, the highest Beneish M-Score of Chengdu Easton Biopharmaceuticals Co was 2.40. The lowest was -2.68. And the median was -2.23.


Chengdu Easton Biopharmaceuticals Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Chengdu Easton Biopharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Easton Biopharmaceuticals Co Beneish M-Score Chart

Chengdu Easton Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.16 -1.87 -2.53 -1.92 -2.20

Chengdu Easton Biopharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.27 -2.68 -2.65 -2.20 -2.26

SHSE:688513 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chengdu Easton Biopharmaceuticals Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Beneish M-Score falls into.


SHSE:688513
95GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Easton Biopharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chengdu Easton Biopharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8325+0.528 * 0.9979+0.404 * 1.8857+0.892 * 1.0087+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9413+4.679 * -0.009858-0.327 * 0.8519
=-2.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥214 Mil.
Revenue was 326.263 + 312.257 + 364.685 + 348.808 = ¥1,352 Mil.
Gross Profit was 252.643 + 230.478 + 275.273 + 254.195 = ¥1,013 Mil.
Total Current Assets was ¥2,117 Mil.
Total Assets was ¥3,777 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,213 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥388 Mil.
Total Current Liabilities was ¥554 Mil.
Long-Term Debt & Capital Lease Obligation was ¥32 Mil.
Net Income was 50.831 + 63.897 + 83.591 + 75.982 = ¥274 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 95.556 + 46.123 + 61.346 + 108.515 = ¥312 Mil.
Total Receivables was ¥255 Mil.
Revenue was 305.64 + 309.818 + 370.423 + 354.524 = ¥1,340 Mil.
Gross Profit was 241.929 + 204.824 + 286.098 + 268.952 = ¥1,002 Mil.
Total Current Assets was ¥1,997 Mil.
Total Assets was ¥3,461 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,246 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥409 Mil.
Total Current Liabilities was ¥593 Mil.
Long-Term Debt & Capital Lease Obligation was ¥36 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(213.907 / 1352.013) / (254.749 / 1340.405)
=0.158214 / 0.190054
=0.8325

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1001.803 / 1340.405) / (1012.589 / 1352.013)
=0.747388 / 0.748949
=0.9979

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2117.374 + 1212.575) / 3777.445) / (1 - (1997.069 + 1246.356) / 3460.845)
=0.118465 / 0.062823
=1.8857

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1352.013 / 1340.405
=1.0087

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1246.356)) / (0 / (0 + 1212.575))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(387.966 / 1352.013) / (408.616 / 1340.405)
=0.286954 / 0.304845
=0.9413

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((31.555 + 553.638) / 3777.445) / ((35.962 + 593.427) / 3460.845)
=0.154918 / 0.18186
=0.8519

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(274.301 - 0 - 311.54) / 3777.445
=-0.009858

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Chengdu Easton Biopharmaceuticals Co has a M-score of -2.26 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.26 mean?
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Beneish M-Score of -2.26 as of Jul. 07, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #442 out of 824 companies in the Biotechnology industry, placing it in the top 53.6%.
Is Chengdu Easton Biopharmaceuticals Co's Beneish M-Score too high?
Chengdu Easton Biopharmaceuticals Co's current Beneish M-Score is -2.26. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #442 out of 824 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #442 out of 824 companies for Beneish M-Score. This places Chengdu Easton Biopharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Beneish M-Score is -2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥47.90, compared to a current price of ¥55.10 — trading 15% above its estimated fair value. The current Beneish M-Score is -2.26. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Beneish M-Score is -2.26 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued. The current stock price of ¥55.10 is trading 15% above its estimated GF Value™ of ¥47.90. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.

Key valuation signals for SHSE:688513:

  • Beneish M-Score: -2.26
  • GF Value™: ¥47.90 vs. price of ¥55.10 (15% above fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score

Get the complete analysis for SHSE:688513

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥55.10
Price
¥47.90
GF Value